Danish Medtech ApS will be spun out of Waturu Holding A/S, as the company´s business area requires a different type of organization and competencies.
The Board of Directors has decided that Danish Medtech shall raise capital, which can secure the company towards a commercialization of the company's products through a stock exchange listing at the end of 2020. There is a dialogue with several possible CEO candidates, with industry experience that can provide the company with the necessary knowledge about the market and internationalization.
Waturu Holding A/S and Belair Medical ApS (Dr. Med., Professor Peter Bjerring), will participate in the capital increase and there are advance commitments from a number of investors.
A valuation of the company of DKK 65 million and a Pre-IPO capital increase of DKK 10 million is expected. Waturu Holding A/S will remain the majority owner after the funding.
Waturu Holding A/S will regularly inform about the development and the transaction is expected to be completed by 31 October 2019.
Investors who wish to participate as Pre-IPO investors can send contact information to info@danishmedtech.com, for more information.
About Danish Medtech
Danish Medtech ApS is owned by Waturu Holding A/S and Belair Medical ApS with 90% and 10% respectively. Behind Belair Medical stands Dr. Professor Peter Bjerring who specializes in the treatment of inflammatory skin diseases.
Danish Medtech develops solutions that can ensure a better wound care treatment and research into the development of a new treatment for patients with inflammatory skin diseases such as children's eczema.
Wound care is costly and the average treatment in Europe costs approx. DKK 50,000 per patient. Danish Medtech develops a new wound-rinse product for home treatment, which can ensure that the cleansing of wounds takes place with germ-free and temperate water, which can help for faster wound healing with less scar tissue.
Eczema is a disease that affects many patients and alone in Europe, more than 100 million people are affected by eczema. Danish Medtech is developing a product that treats the inflammation and can be used in the home and fits into the patient's daily life. To be able to get approval of the product, a number of clinical tests must be carried out, which will be initiated in 2019/2020.
For further information:
CEO Toke Reedtz, cell.: +45 5188 1262, e-mail: toke@waturu.com
CFO Michael Nørgaard, cell.: +45 2720 6214, e-mail: mn@waturu.com
Waturu Holding A/S
Sjællandsgade 32
7100 Vejle
www.waturu.com
Certified Adviser:
Västra Hammen Corporate Finance AB
Jungmansgatan 12
211 11 Malmö
www.vhcorp.se